Review Article

Stroke Associated with COVID-19 Vaccines

Maryam Kakovan,a Samaneh Ghorbani Shirkouhi,b,c Mojtaba Zarei,d,e,f and

Sasan Andalib,f,g,h,i,j

Objectives: Development of safe and effective vaccines against coronavirus disease

2019 (COVID-19) remains the cornerstone of controlling this pandemic. However,
there are increasing reports of various types of stroke including ischemic stroke,
and hemorrhagic stroke, as well as cerebral venous sinus thrombosis (CVST) after
COVID-19 vaccination. This paper aims to review reports of stroke associated with
COVID-19 vaccines and provide a coherent clinical picture of this condition. Materi-
als and methods: A literature review was performed with a focus on data from recent
studies. Results: Most of such patients are women under 60 years of age and who
had received ChAdOx1 nCoV-19 vaccine. Most studies reported CVST with or
without secondary ischemic or hemorrhagic stroke, and some with Vaccine-
induced Thrombotic Thrombocytopenia (VITT). The most common clinical symp-
tom of CVST seen after COVID-19 vaccination was headache. The clinical course of
CVST after COVID-19 vaccination may be more severe than CVST not associated
with COVID vaccination. Management of CVST following COVID-19 vaccination
is challenging and may differ from the standard treatment of CVST. Low molecular
weight heparin is commonly used in the treatment of CVST; however, it may
worsen outcomes in CVST associated with VITT. Furthermore, administration of
intravenous immunoglobulin and high-dose glucocorticoids have been recom-
mended with various success rates. Conclusion: These contradictory observations
are a source of confusion in clinical decision-making and warrant further study and
development of clinical guidelines. Clinicians should be aware of clinical presenta-
tion, diagnosis, and management of stroke associated with COVID-19 vaccination.
Key Words: COVID-19—Vaccination—Stroke—Thrombosis
© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/)

From the aSchool of Medicine, Guilan University of Medical Sciences, Rasht, Iran; bSchool of Medicine, Shahroud University of Medical Sciences,
Shahroud, Iran ; cNeuroscience Research Center, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; dInsti-
tute of Medical Science and Technology, Shahid Beheshti University, Tehran, Iran; eDepartment of Neurology, Odense University Hospital, Univer-
sity of Southern Denmark, Odense, Denmark; fDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark; gResearch
Unit of Clinical Physiology and Nuclear Medicine, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; hSteno Diabe-
tes Center Odense, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; iBRIDGE: Brain Research Interdisci-
plinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; and jNeuroscience Research
Center, Guilan University of Medical Sciences, Rasht, Iran.
Received September 23, 2021; revision received November 28, 2021; accepted December 11, 2021.
Address correspondence to Department of Clinical Research, University of Southern Denmark, Odense, Denmark. E-mail: [email protected].
1052-3057/$ - see front matter
© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106440

Journal of Stroke and Cerebrovascular Diseases, Vol. 31, No. 6 (June), 2022: 106440 1
2 M. KAKOVAN ET AL.

Introduction mRNA COVID-19 vaccines namely Pfizer-BioNTech

(BNT162b2) and the Moderna (mRNA-1273) give the cells
In the past two decades, coronaviruses have caused two
instructions to make S protein which may generate anti-
serious pandemics, namely severe acute respiratory syn-
bodies. After delivering instructions, the mRNA is broken
drome (SARS) and Middle East Respiratory Syndrome
down immediately and does not enter the nucleus of the
(MERS).1,2 Severe acute respiratory syndrome coronavi-
host cells. In vector COVID-19 vaccines viz Ad26.COV2.S,
rus-2 (SARS-CoV-2) caused coronavirus disease 2019
Sputnik V (rAd26-S and rAd5-S), and ChAdOx1 nCoV-19
(COVID-19) in late 2019, which was later turned into a
SARS-COV-2’s, genetic material is inserted in a viral vec-
pandemic in March, 2020.3 COVID-19 is now a global
tor. The vector delivers the genetic material to the host
health issue4,5 for which control measures such as the use
cells that make copies of the S protein on their surfaces.
of face masks, physical distancing, testing of exposed or
The immune system then responds by creating antibodies
symptomatic individuals, contact tracing, and quarantine
and defensive white blood cells. Protein subunit COVID-
seem insufficient.6 14 Despite numerous efforts, there is
19 vaccines such as Novavax (NVX-CoV2373) include
no cure for the disease.15 Thus far, vaccination has been
only harmless S protein which stimulates the immune sys-
the best strategy to end this pandemic; however, vaccina-
tem. Inactivated or weakened COVID-19 vaccines do not
tion hesitancy can jeopardize the success of COVID-19
cause disease, but still, stimulate the immune system.
immunization programs.16 Several COVID 19 vaccines
have been developed and launched into the market, and
Vaccine-induced neurological complications
some are still in the process of clinical trials. Information
on vaccine safety or adverse effects has important impacts SARS-CoV-2 infection induces important changes in the
on public acceptance of the vaccines.17,18 innate and adaptive immunity.31 It results in overproduc-
COVID-19 produces various neurological tion of proinflammatory cytokines including interleukins
manifestations.19,20 Stroke is an important neurological (e.g., IL-1a, IL-1b, IL-6, IL-7), chemokines (e.g., CXCL1,
complication of COVID-19 in the central nervous system CXCL2, CXCL6, CXCL8 /IL-8, CXCL10, CCL2/ MCP-1,
(CNS),20,21 but it also occurs subsequent to COVID-19 CCL3 / MCP-1 A, CCL4/ MIP1B), and interferons (e.g.,
vaccination.22 Ischemic stroke and intracerebral hemor- IFN-a2, IFN-b1, IFN-2).32,33 Serum IL-6, a reliable prog-
rhage (ICH)23have been reported after COVID-19 vaccina- nostic factor for ischemic stroke,20 rises in COVID-19.34 It
tion.24 Cerebrovascular venous sinus thrombosis (CVST) is thought that at least some neurological symptoms such
was first reported after Oxford-AstraZeneca vaccine inoc- as inflammation of the peripheral and central nervous sys-
ulation (ChAdOx1 nCoV-19). Subsequently, 6 cases of tems are due to the release of these factors.35 Moreover,
CVST were reported after administration of Johnson & lung tissue involvement can lead to hypoxia in the CNS
Johnson vaccination (Ad26.COV2.S).25 which can present with sensory, cognitive, and motor
Vaccine-induced Thrombotic Thrombocytopenia (VITT) impairment.36
may also be associated with stroke following COVID-19 Vaccination induces a series of immunological events
vaccination.26 28 Management and treatment of stroke are which may cause neurological problems, for example,
usually challenging, but it is more so in VITT-associated demyelinating diseases,37 40 epileptic seizures,41 Guillain-
stroke. This review paper summarizes reports of stroke Barre syndrome,42 and stroke.43 The most common neuro-
after COVID-19 vaccination and gives account of its clini- logical symptoms after the vaccination include dizziness,
cal picture, management, and treatment. For this review, headache, pain, muscle spasms, myalgia, and paresthesia,
we searched PubMed and Google Scholar databases for which are usually acute and transient.43 Furthermore, in
the following keywords: Stroke, cerebral venous sinus limited studies, tremor, diplopia, tinnitus, dysphonia, and
thrombosis, CVST, cerebral venous thrombosis, CVT, cere- seizures were seen after COVID-19 vaccination.43 In a trial
brovascular accident, CVA, cerebrovascular event, throm- of the Pfizer BioNTech (BNT162b2) mRNA vaccine, 7 out
bosis, ischemic stroke, intracerebral hemorrhage, of 37,000 participants developed Bell’s palsy, although the
intracranial hemorrhage, ICH, hemorrhage, vaccine, rate of the disease was not higher than expected in the
COVID-19, SARS-CoV-2, corona, complication, side effect. general population.44

Different types of COVID-19 vaccines: how Stroke following COVID-19 vaccination

they work
Stroke is a major cause of death and disability glob-
COVID-19 vaccines motivate the immune system to cre- ally.45 It can be classified into two main categories of
ate antibodies against SARS-CoV-2. The vaccines use a ischemic and hemorrhagic stroke, the latter has higher
harmless structure similar to spike (S) protein, which is mortality than the former.46 CVST is a rare form of stroke
present on the surface of SARS-CoV-2 and is used for viral that is generally seen in younger patients and predomi-
endocytosis to the host cells. The COVID-19 vaccines nantly women.47 49 COVID-19 vaccines may trigger
include messenger RNA (mRNA), vector, protein subunit, stroke with thrombotic thrombocytopenia with or with-
and inactivated/weakened vaccines.29,30 Engineered out the presence of anti-platelet factor 4 antibody (anti-
STROKE ASSOCIATED WITH COVID-19 VACCINES 3

PF4 antibody). Such association between thrombocytope- Ischemic stroke after COVID-19 vaccination
nia and thrombosis with a catastrophic clinical picture has
In ischemic stroke, a region of the brain is dispossessed
raised clinical attention. Association of thrombosis and
of blood flow which can be due to thrombosis of an artery
thrombocytopenia rarely occurs in thrombotic thrombo-
or, in rare instances, a vein. Thrombosis can occur in the
cytopenic purpura, heparin-induced thrombocytopenia
vessels following COVID-19 vaccination. They are usually
(HIT), autoimmune HIT, antiphospholipid syndrome
seen in the context of VITT. These cases were mostly diag-
(APS),50 and disseminated intravascular coagulation
nosed following ChAdOx1 nCoV-19 vaccine, especially
(DIC).51 Unusual thrombotic events with thrombocytope-
with the involvement of the middle cerebral artery
nia following COVID-19 vaccination and the presence of
(MCA). The emergence of persistent or unusual neurolog-
anti-PF4 antibody have led to the concept of VITT, which
ical symptoms after receiving the COVID-19 vaccines
is also called thrombosis with thrombocytopenia syn-
should urgently be evaluated for VITT with neuroimag-
drome (TTS).52 The clinical picture mirrors what is seen in
ing techniques and laboratory tests.
HIT.53 Anti-PF4 antibodies are typically detected in HIT54
De Michele et al.64 carried out clot analysis after throm-
probably due to molecular mimicry between proteins on
bectomy in patients with ischemic stroke following the
the virus and platelet antigens,55,56 On another reading,
ChAdOx1 nCoV-19 vaccine and suggested that the clot
the antibodies produced against the spike (S) proteins
collected during the first thrombectomy was mainly com-
might cross-react with specific antigens expressed on the
posed of platelets (85% of the total material examined)
platelet surface.28 However, in one preliminary report,
and was massively infiltrated by neutrophils with scarce
Greinacher et al.57 suggested that anti-PF4 antibody do
evidence of karyorrhexis. Histological features consistent
not cross-react with the S protein.
with the presence of neutrophil DNA extracellular traps
Another hypothesis is that the breakdown of fibrin
(NETs) were also observed. Furthermore, the clot col-
leads to the production of D-dimer.58 Elevated D-dimer
lected during the second endovascular procedure was a
associated with thrombocytopenia is suggestive of activa-
red-blood-cell-rich thrombus (90% of red blood cells and
tion of systemic anticoagulation. Therefore, increased D-
10% fibrin and platelets) with scarce neutrophils. Nor-
dimer level may be a helpful parameter to distinguish idi-
mally, platelet-rich thrombi are formed by Von Wille-
opathic primary thrombocytopenia from secondary
brand factor, neutrophil extracellular traps, and fibrin.65
thrombocytopenia due to systemic thrombosis.58 Further-
However, platelet/fibrin thrombi were also found in
more, CSVT incidence is significantly correlated with D-
veins and arteries of multiple organs,66 so-called “white
dimer level.59
clot syndrome”.67 Despite this, it would be difficult to
A prospective Chinese cohort study suggested that
account for their potential pathophysiological differences.
inactivated COVID-19 vaccine (BBIBP-CorV, Sinopharm)
In fact, the main difference between the clots is their age.64
did not influence the profile of antiphospholipid antibody
Table 1 shows that most of the patients with ischemic
and anti-PF4-heparin antibody nor increased the risk of
stroke after COVID-19 vaccination were women within
thrombosis.60 Additionally, Campello et al.61 suggested
the age range of 26-60 years and after vaccination with
that significant activation of fibrinogen-driven coagula-
ChAdOx1 nCoV-19 vaccines and within 1 to 21 days after
tion, plasma thrombin generation, or clinically meaning-
the vaccination.
ful platelet aggregation did not occur after ChAdOx1
nCoV-19 or BNT162b2 vaccination. Nevertheless, Simp-
Hemorrhagic stroke after COVID-19
son et al.62 evaluated associations between ChAdOx1
vaccination
nCoV-19 or BNT162b2 vaccination and hematological
and vascular adverse events. They demonstrated an asso- Hemorrhagic strokes occur when a blood vessel rup-
ciation between vaccination with ChAdOx1 (but not vac- tures. ICH and subarachnoid hemorrhage (SAH) can
cination with BNT162b2) and idiopathic occur after COVID-19 vaccination, which can be primary
thrombocytopenic purpura (ITP), arterial thromboembolic or secondary to venous thrombosis.23,71 76 While ICH
events and hemorrhagic events. after COVID-19 vaccination can occur in the context of
Using an animal model, Nicolai et al.63 showed that VITT, Silva et al.75 described primary hemorrhagic stroke
intravenous injection of ChAdOx1 nCov-19 triggers plate- following ChAdOx1 nCoV-19 vaccination in a patient
let-targeted autoimmunity in the spleen that may result in without thrombocytopenia, coagulation disorder, or coag-
thrombocytopenia syndrome. Hence, aspiration (to ulation risk factors. Argument for such a causal relation is
ensure the needle is not in a blood vessel) prior to injection that arterial hypertension77 and ICH23,78 are complica-
of the vaccine could be a potential preventive measure for tions of COVID-19 vaccination. More to the point, hyper-
this important side effect. tension is an important risk factor of ICH.
Most of the reports of stroke after COVID-19 are from Finsterer et al.79 suggested that the second dose of
Europe. In addition, most of the patients were women SARS-CoV-2 vaccination may be followed by ICH even
within an age range of 18-77 years and within 1-24 days when the first dose was uneventful Table 2. summarizes
after the ChAdOx1 nCov-19 vaccination. reports of ICH following COVID-19 vaccination. As can
 4
Table 1. Summary of reports of ischemic stroke cases following the COVID-19 vaccination.

Vaccine Number Age Gender Interval (days) Clinical Imaging and lab findings Treatment Outcome Author, year, ref
of cases (F, M) between presentation
vaccination and
diagnosis
ChAdOx1 3 35-43 11-21 Case 1: headache, Case 1: MCA infarct Case 1: IVIg, plasma- Case1: death Al-Mayhani
nCoV-19 F = 2, M = 1 left hemiparesis, Case 2: ICA infart and CVST pheresis, Fondapari- Case 2: improved et al., 202127
(AstraZeneca) right gaze prefer-Case 3: MCA infarct nux, and clinically
ence, and drowsi- Thrombocytopenia, positive decompressive hemi- Case3: discharged
ness anti-PF4 antibody, and craniectomy with favorable
Case 2: diffuse increased D-dimer in all Case2: IVIg, plasma- clinical outcome
headache, left three patients pheresis, methyl-
visual field loss, prednisolone, and
confusion, and Fondaparinux
left arm weakness Case 3: platelet trans-
Case 3: dysphasia fusion, IVIg, and
Fondaparinux
1 60 8 headache and left- Ischemic stroke in the terri- Hydrocortisone, plate- Death Blauenfeldt
F=1 weakness and eye tory of ICA and MCA let concentrates, et al., 2021
deviation to the Thrombocytopenia, positive hemicraniectomy, (53)
right anti-PF4 antibody, and and dalteparin
increased D-dimer
1 26 1 Persistent nausea Ischemic stroke in the terri- Corticosteroids, plas- Only gripping difficul- Garnier et al.,
F=1 and headache and tory of MCA matic exchange, and ties and minor phasic 202168
right hemiplegia Thrombocytopenia, positive anticoagulants troubles were
and aphasia anti-PF4 antibody, remaining
decreased fibrinogen level
23 21-77 6-24 (mean:12) NM Thirteen cases of CVST NM Seven patients died Scully et al.,
(mean:46) Two cases of ischemic stroke 202169
F = 14 M = 9 antiPF4 antibody was posi-
tive in 22 patients
Thrombocytopenia in 22
patients, low fibrinogen
levels in 13 patients, and
increased D-dimer levels in

M. KAKOVAN ET AL.
21 patients
1 31 8 Acute headache, Occlusion of MCA with the IV thrombolysis, Aspi- Favorable clinical Walter et al.,
M=1 aphasia, and source of thrombus ipsilat- rin, Danaparoid, outcome 202170
hemiparesis eral in the carotid bulb, Phenprocoumon
elevated D-dimer level
slightly, and positive anti-
PF-4 antibody
STROKE ASSOCIATED WITH COVID-19 VACCINES 5

be noted, most of the cases were reported following

Author, year, ref

et al., 202164
administration of ChAdOx1 nCoV-19 vaccine and in peo-

De Michele

Note: MCA: Middle Cerebral Artery; CVST: Cerebral Venous Sinus Thrombosis; Anti-PF4-antibody: anti-platelet factor 4 antibody; IVIg: Intravenous Immunoglobulin; IV: Intravenous.
ple 30 57 years of age, 5 12 days after the vaccination
Table 2. shows the summary of reports of ICH following
the COVID-19 vaccination.

Cerebral venous sinus thrombosis after

let transfusion, IVbe- Case 2: Brain death
COVID-19 vaccination
Case 1: critical

CVST is a rare form of stroke occurring often in young

thrombectomy, plate- condition
Outcome

and middle-aged women.81 Partial or complete occlusion

of cerebral venous sinus system or its small-caliber drain-
ing veins leads to venous hypertension, localized paren-
chymal edema, raised intracranial pressure (ICP),
tamethasone, IVIg,

infarction, and rarely ICH. The most common manifesta-

plasma exchange,
Case 1: mechanical

tion of CVST is headache,82 which may be generalized or

dexamethasone
Case 2: IVIg and
fondaparinux

focal and is often progressive. CVST has been reported in

Treatment

COVID-19 patients and is paradoxically associated with

thrombocytopenia.55,83 This phenomenon can be
explained by systemic platelet consumption and seques-
tration through agglutination triggered by COVID-19 vac-
cine immunization process, which may lead to
plegia, right gaze Thrombocytopenia, positive

increased D-dimer level

thrombosis.58 The peculiarities of CVST following

Imaging and lab findings

anti-PF4 antibody, and

COVID-19 vaccination warranted the specific term of

VITT.58 VITT is characterized by its unusual sites of
Table 1 (Continued)

Ischemic stroke

thrombosis and the absence of common risk factors of

CVST after COVID-19 vaccination in these patients. The
unusual sites can include the cerebral venous sinus,
splanchnic venous system, pulmonary thromboembolism
(PTE), deep vein thrombosis (DVT), or acute arterial
thrombosis.28,78,84 87 CVST after COVID-19 vaccination
right hemiparesis,
generalized seiz-
deviation, dysar-
Case 1: left hemi-

was first reported following vaccination with ChAdOx1

ures, and coma
Case 2: aphasia,
thria, and left

nCoV-19; however, it was subsequently reported follow-

presentation

ing adenovirus-based vaccine Ad26.COV2.S.88 European

neglect
Clinical

Medicines Agency (EMA) reported 169 possible cases of

CVST from 34 million recipients of the ChAdOx1 nCoV-
19 vaccine; 35 possible cases of CVST from 54 million
vaccination and

recipients of the BNT162b2 mRNA vaccine, and 5 possi-

Interval (days)

Case 2 = 10

ble, but unvetted, cases of CVST from 4 million recipients

Case 1 = 9,
diagnosis

of the mRNA-1273 vaccine.28 Six possible cases of CVST

between

were reported from more than 7 million recipients of the

Ad26.COV2.S vaccine.28
The frequency of atypical thrombosis after COVID-19
Case 2 = 57
Case 1 = 55,
Number Age Gender

vaccination should be weighed against thrombosis in the

general population. These statistics should be considered
of cases (F, M)

in comparison with stroke that occurs in patients with

F=2

COVID-19. In these patients, thrombosis occurs at least

100-fold more often in the unvaccinated people compared
to the vaccinated.89 According to EMA data, of nearly
25 million people vaccinated with ChAdOx1 nCoV-19
2

vaccine in the UK, 62 developed CVT, and 24 had

splanchnic venous thrombosis. The incidence of CVT in
the vaccinated people was 2.6 per million people within
Vaccine

4-month after vaccination with ChAdOx1 nCoV-19 vac-

cine. However, the estimated incidence of CVT was 3-4
cases per million per year in unselected populations.90 In
6 M. KAKOVAN ET AL.

contrast, mRNA vaccines, compared to hormonal con- patients were female at 18-77 years of age. Most of these
traceptive use, do not show a disproportional rate of CVST cases were reported following ChAdOx1 nCoV-19
thromboembolic events in younger women.91 vaccine administration. Moreover, these patients received
A multicenter cohort study92 collected data from 43 the vaccine 2-24 days before the diagnosis of stroke.
hospitals across the UK and between April 1st and May
20th, 2021, reporting 95 patients with stroke, of which 70
Comparison of different vaccines associated
had VITT. The median age of the VITT group was
with stroke
47 years, compared to that in the non-VITT group, which
was 57 years (p=0¢005). The primary outcome of death or Since the basic characteristics of vaccine recipients are
dependency occurred more frequently in the patients different, it is not easy to compare various COVID-19 vac-
with VITT-associated CVT (33/70), compared with the cines triggering stroke. The manufacturing technology for
non-VITT control group (4/25) (p=0¢0061). This adverse mRNA-based vaccines is different from that for adenovi-
outcome was less frequent in the patients with VITT who rus-based vaccines, and hence the mechanism of thrombo-
received non-heparin anticoagulants (18/50), compared sis formation differs in these vaccines.112 CVST after
with those who did not receive non-heparin anticoagu- ChAdOx1 nCov-19 vaccination is more frequent and is
lants (15/20) (p=0¢0031), and in those who received IVIg associated with venous thrombotic events and a higher
(22/55), compared with those who did not receive IVIg mortality rate than that after the BNT162b2 and mRNA-
(11/15) (p=0¢022). In this study, it was also suggested 1273 vaccines.94 In addition, thrombocytopenia and posi-
that non-heparin anticoagulants and immunoglobulin tive anti-PF4 antibodies have been reported more fre-
treatment might improve outcomes of VITT-associated quently after the ChAdOx1 nCov-19 vaccine than after
CVT. the mRNA-based vaccine.94 Furthermore, the clinical
CVST after vaccination mostly occurs with adenoviral manifestations of CVST after ChAdOx1 nCov-19 vaccine
COVID-19 vector vaccines, especially ChAdOx1 nCoV-19 and mRNA-based vaccine are different. CVST after ChA-
vaccine; nonetheless, CVST may also occur following dOx1 nCov-19 vaccination has a clinical picture different
mRNA-based COVID-19 vaccines. rAd26-S and rAd5-S is from CVST patients unrelated to vaccination; however,
another recombinant adenovirus vaccine but no CVT CVST which occurs after receiving mRNA vaccines is sim-
cases have been reported following its use. Nonetheless, ilar to pre-COVID-19 CVST cases unrelated to vaccina-
that is not to say that CVT does not occur following this tion.94 These differences can even extend to differences
vaccine. between vaccines that are made with similar technology.
CVST usually has a good prognosis. However, CVST Indeed, patients who received the Ad26.COV.2.S vaccine
after COVID-19 vaccination may follow a catastrophic tend to develop clinical manifestations later than those
course. The outcome for these patients may be poor due receiving ChAdOx1 nCoV-19.114 Additionally, D-dimer
to refractory increased ICP; indeed, almost half of patients and activated Partial Thromboplastin Time (aPTT) levels
with CVT in the context of VITT die within a few days might be lower in patients after Ad26.COV.2.S than sub-
and death often occurs following brain infarction often jects receiving ChAdOx1 nCoV-19.114 Also, the probabil-
associated with ICH.69,78,93 ity of a positive platelet function test in ChAdOx1 nCoV-
Table 3 summarizes reports of CVST following the 19 recipients is much higher than in the Ad26.COV.2.S
COVID-19 vaccination. The table shows that most of the recipients; nonetheless, in both groups, most patients are
patients were female at 24-56 years of age. Most of these positive for HIT antibody test using ELISA.114 Notably,
CVST cases were reported following ChAdOx1 nCoV-19 patients with CVT after Ad26.COV.2.S administration is
vaccine administration. Furthermore, all of the patients more likely to suffer ICH and internal jugular vein throm-
received the vaccine 7-20 days before the diagnosis of bosis than those with CVT after ChAdOx1 nCoV-19.114
stroke. There are no significant differences between the two vac-
cines in mortality and presenting symptoms, viz head-
ache, visual disturbance, hemiparesis, and fever.114
Ischemic and hemorrhagic stroke subsequet
Beyond the comparison between different COVID-19 vac-
to CVST after COVID-19 vaccination
cines, Pawlowski et al.115 assessed the association of
Ischemic or hemorrhagic stroke may occur with CVST COVID-19 vaccines and non-COVID-19 vaccines with
subsequent to COVID-19 vaccination. Obstruction of the CVST in a cohort of 771,805 vaccination events across
brain’s venous system increases ICP and may rupture 266,094 patients in the Mayo Clinic Health System
blood vessels leading to hemorrhagic stroke. Further- between 01/01/2017 and 03/15/2021 and found that the
more, hypercoagulable state may cause further clot for- risk of CVST is similar in the 30 days prior to COVID-19
mation causing ischemic stroke. These complications have vaccination compared to that in the 30 days after vaccina-
a direct impact on the treatment strategy. tion. In addition, the risk of CVST within 30 days follow-
Table 4 summarizes reports of CVST with ischemic or ing COVID-19 vaccination is similar to the risk of CVST
hemorrhagic stroke. The table shows that most of the within 30 days after all analyzed non-COVID
 STROKE ASSOCIATED WITH COVID-19 VACCINES
Table 2. Summary of reports of ICH following the COVID-19 vaccination.

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author, year, ref
cases (F, M) between vaccina-
tion and diagnosis
ChAdOx1 1 In her thir- 10 Headache, lethargy, ICH (MCA) IV tranexamic acid Death Bjørnstad et al.,
nCoV-19 ties uncoordinated move- Thrombocytopenia and 202123
(AstraZeneca) F=1 ments, reduced con- positive anti-PF4 anti-
sciousness, aphasia, body
central left facial Thrombi in the transverse
paresis with right gaze sinus in autopsy
deviation, and left
hemiparalysis
1 57 5 Fever, headache, left ICH Decompressive On Day 15 left hemi- Silva et al.,
F=1 hemiparesis, vomiting, craniectomy paretic, obeying sim- 202175
and somnolence ple tasks, kept on
tracheostomy
mRNA-based 1 52 7 aphasia ICH in temporal lobe Sacubitril/valsartan, Aphasia resolved Finsterer et al.,
SARS-CoV-2 M=1 atorvastatin, and 202179
vaccine bisoprolol in the
rehabilitation
1 52 12 Intense headache, GCS;6 ICH Tranexamic acid, Death Wolthers
ChAdOx1 M=1 Thrombocytopenia, ele- platelet concentrate et al.,202180
nCoV-19 vated fibrin D-dimer
(Vaxzervia) level, low fibrinogen
level, slightly increased
INR
Note: MCA: Middle Cerebral Artery; Anti-PF4-antibody: anti-platelet factor 4 antibody; ICH: Intracerebral Hemorrhage; INR: International Normalized Ratio; IV: Intravenous; GCS: Glasgow
Coma Scale.

7
8 M. KAKOVAN ET AL.

vaccinations. Finally, the authors suggested that CVST is present 5 28 days after vaccination and are characterized
rare and not significantly associated with COVID-19 vac- by thrombocytopenia, elevated D-dimer level and throm-
cination in their study. bosis, which often rapidly deteriorate (definite case). In
addition to diagnostic criteria and laboratory findings,
radiological imaging should be used to confirm the diag-
Recommendations for diagnosis and
nosis. In the event of acute onset of CVST, a non-contrast
management of CVST after COVID-19
brain computed tomography (CT) should be the first eval-
vaccination
uation. Nevertheless, a non-contrast CT has poor sensitiv-
Many cases of stroke after COVID-19 vaccination is ity since it only displays indirect and suggestive
associated with VITT. Following the first post-COVID-19 alterations of CVST in 30% of patients.118 Consequently, if
vaccination VITT reports several international scientific CVST is suspected, non-contrast CT should be carried out
societies and panels of experts made recommendations on along with a contrast CT scan to create a three-dimen-
the management of patients with suspected VITT syn- sional venous reconstruction (CT venography).119 124 In
drome from diagnosis to treatment. Management of patients with subacute onset, magnetic resonance imaging
stroke associated with VITT is challenging and complex. (MRI) is, however, the study of choice.118 In a meta-analy-
In addition, clinicians should be aware that management sis study, CT and MRI showed similar diagnostic perfor-
recommendations of CVST after COVID-19 vaccination mance for CVST diagnosis.123 Although Kennedy et al.125
markedly differ from the routine treatment of CVST. reported a case of VITT following Ad26.COV2.S COVID-
The diagnosis of VITT is rather challenging owing to its 19 vaccination without radiographically thrombosis
diverse clinical manifestations. Clinicians should maintain demonstrable by radiography (Brain MRI) at presenta-
a high degree of suspicion in patients with symptoms sug- tion. Withal, Ikenberg et al.76 reported a patient whose ini-
gestive of thrombotic events after COVID-19 vaccination, tial brain MRI was seemingly normal, but follow-up brain
and along with this, wise comprehensive diagnostic crite- MRI findings indicated an extensive CVST, and labora-
ria can be advantageous. The Expert Hematology Panel tory report confirmed VITT. Therefore, if clinical suspi-
(EHP) of UK116 and the American Society of Hematology cion of CVST after COVID-19 persists, a repeat MRI is
(ASH)117 produced recommendations for the diagnosis of useful.
VITT that included receipt of a COVID-19 vaccine (Jans- Treatment of stroke in the setting of VITT is challeng-
sen/Vaxzevria) 4 to 30 days previously, thrombosis (often ing. What is important is to act according to the existing
cerebral or abdominal), thrombocytopenia, and positive guidelines considering the specific condition of each
PF4-HIT test using ELISA. They also recommended patient. The key element of management of VITT-associ-
urgent medical evaluation for VITT if any of the symp- ated CVT is high-dose IVIg and anticoagulation using
toms including severe headache, visual changes, abdomi- direct oral anticoagulants.86,126,127 The use of non-heparin
nal pain, nausea and/or vomiting, backache, shortness of anticoagulants and IVIg can be related to a low probabil-
breath, leg pain or swelling, petechiae, or easy bruising ity of VITT-associated CVT death or dependency at the
develop 4 to 30 days after vaccination. Urgent diagnostic end of hospital admission.92 IVIg prevents platelet activa-
workup in suspected VITT also includes complete blood tion by PF4 antibodies and rapidly restores the platelet
count (CBC) and peripheral blood smear, PF4-ELISA (HIT count.105 Immune globulin prevents antibody-mediated
assay) using blood drawn prior to any therapies, fibrino- platelet clearance and may down-regulate platelet activa-
gen level, and imaging for thrombosis based on signs/ tion by immune complexes by blocking platelet FcRgIIA
symptoms.116,117 In addition to the above-mentioned rec- receptors.127 Therefore, prompt initiation of IVIg (1g/kg
ommendations for lab tests, a D-dimer check seems useful over two days if needed) that is likely to influence the dis-
for the diagnosis of VITT associated with COVID-19 vac- ease process, regardless of the severity of thrombocytope-
cination. Scully et al.69 demonstrated that D-dimer levels nia, and continuing to review the clinical course, is
in patients with thrombosis and thrombocytopenia after recommended for VITT.128 Contrastingly, clinicians
receiving the ChAdOx1 nCoV-19 vaccine were much should avoid all forms of heparin (i.e. unfractionated hep-
higher than what was expected in patients with acute arin, even for line flushes, or LMWH e.g. enoxaparin) in
venous thromboembolism. In addition, the EHP116 classi- VITT-associated CVT.74 However, non-heparin-based
fies clinical presentation of VITT as follows: patients pre- anticoagulants such as direct thrombin inhibitors (includ-
senting with acute thrombosis and new-onset ing bivalirudin, argatroban, and dabigatran), direct factor
thrombocytopenia within 28 days of receiving COVID-19 Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban),
vaccination (possible case), patients with either a low and indirect antithrombin dependent Xa inhibitors (e.g.,
platelet count without thrombosis or with a D-dimer fondaparinux) are not contraindicated in VITT.129 Admin-
count at or about normal levels (< 2000 mg/L) but with istration of anticoagulation should not be avoided in
and normal fibrinogen (2 4 g/L) levels (unlikely case), VITT patients with low fibrinogen levels or bleeding asso-
increased D-dimers (>4000 mg/ L > 2000 with a strong ciated with VITT, particularly if the platelet count is
clinical suspicion) (probable case), and cases usually >20,000/mL or increases following IVIg initiation.116,117
 STROKE ASSOCIATED WITH COVID-19 VACCINES
Table 3. Summary reports of CVST following the COVID-19 vaccination.

Vaccine Number of Age, Gender Interval (days) Clinical presentation Imaging and lab Treatment Outcome Author,
cases (F, M) between findings year, ref
vaccination and
diagnosis
ChAdOx1 nCoV- A total of 213 Median of Nine days in the NM CVST in all of the NM Of the 117 patients with a Krzywicka
19, BNT162b2 ChAdOx1 age: 46 ChAdOx1 patients reported outcome in the et al.,
mRNA, and nCoV-19 (187 75% women nCov-19 Thrombocytopenia in ChAdOx1 nCov- 19 group, 202194
mRNA-1273 patients), in ChA- group and 107 patients amongst 44 died, compared to 2
BNT162b2 dOx1 7 days in the 187 patients receiv- deaths out of 10 deaths with
mRNA (25 nCoV-19 mRNA vac- ing the ChAdOx1 reported outcome in the
patients), and recipients cine group nCoV-19 vaccine mRNA vaccine group and 3
mRNA-1273 and 77% in deaths out of 100 patients
(1 patient) mRNA with reported outcome in
vaccine the pre- COVID- 19 group.
recipients

1 49 20 New-onset of mild to CVST Clexane, clopi- Symptoms gradually Zakaria et

M=1 moderate headache dogrel, and improved al., 202195
and giddiness apixaban
ChAdOx1 nCoV- 1 56 14 Persistent holocranial CVST LMWH and Significant improvement in Dutta et al.,
19 M=1 headache associated warfarin clinical status 202196
(COVISHIELD) with vomiting, and
double vision in hori-
zontal gaze
ChAdOx1 nCoV- 1 52 10 Nausea and thunder- CVST Apixaban and Discharged without any Guan et al.,
19 (AstraZeneca) M=1 clap headache and Thrombocytopenia, IVIg symptoms 202197
pain on the left side positive anti-PF4
of the neck antibody, and ele-
vated D-dimer level
2 NM NM NM CVT Heparin, corti- Death Geeraerts et
thrombocytopenia costeroid, al., 202198
IVIg in one
patient, and
decompressive
craniectomy
in both
patients
(Continued)

9
 10
Table 3 (Continued)

Vaccine Number of Age, Gender Interval (days) Clinical presentation Imaging and lab Treatment Outcome Author,
cases (F, M) between findings year, ref
vaccination and
diagnosis
1 36 14 Fever with vomiting CVST Enoxaparin, Death Aladdin et
F=1 and severe headache, Thrombocytopenia, antibiotics, al., 202199
and hypofibrinogenemia, and antivirals
sudden onset of focal leukocytosis, ane-
left-sided convul- mia, increased D-
sions for 5 min fol- dimer level, and liver
lowed by weakness enzymes, high creati-
in the left arm. nine severe acidosis
(acute kidney injury),
and prolonged PT,
PTT, and INR
2 24,39 8, 12 Case 1: severe holoce- Case 1: CVST Case 1: danapa- Cases 1 and 2: discharged Gattringer
F=2 phalic headache Case 2: CVT with roid, dexa- without any symptoms et al.,
(before admission), related small frontal methasone, 2021100
new left dull occipi- right juxtacortical IVIg, argatro-
tal headache(during hemorrhage ban, and dabi-
admission) Thrombocytopenia, gatran
Case 2: severe persist- positive anti-PF4 Case 2: IVIg,
ing headache antibody, increased dexametha-
D-dimer and sone, and
decreased fibrinogen argatroban
level
Ad26.COV2.S 1 40 12 Headache, sinus pres- CVST Bivalirudin, Resolution of headache and a Clark et al.,
(Johnson & John- F=1 sure, myalgias, and Thrombocytopenia IVIg, steady improvement in lab- 2021101
son/ Jansen) sore throat with ton- increased D-dimer prednisone oratory markers of
sillar exudate, photo- levels, and mild ele- thrombocytopenia
phobia, and vation of serum
intermittent dizziness transaminases

M. KAKOVAN ET AL.
 STROKE ASSOCIATED WITH COVID-19 VACCINES
Table 3 (Continued)

Vaccine Number of Age, Gender Interval (days) Clinical presentation Imaging and lab Treatment Outcome Author,
cases (F, M) between findings year, ref
vaccination and
diagnosis
1 48 14 New-onset headache CVST UFH, Argatro- Remained critically ill Muir et al.,
F=1 Severe thrombocyto- ban and IVIg 2021102
penia, low fibrinogen
level, prolonged acti-
vated partial throm-
boplastin time, and
marked elevation of
the D-dimer level
1 43 10 Generalized CVST IVIg and TIA one day after discharge Malik et al.,
F=1 headache, fever, Thrombocytopenia, fondaparinux 2021103
body aches, chills, positive anti-PF4
and mild dyspnea, antibody, and ele-
and lightheadedness vated D-dimer
level
Note: CVST: Cerebral Venous Sinus Thrombosis; Anti-PF4-antibody: anti-platelet factor 4 antibody; TIA: Transient Ischemic Attack; LMWH:Low Molecular Weight Heparin; IVIg: Intravenous
Immunoglobulin; UFH: Unfractionated Heparin; NM: Not Mentioned; CRP: C-Reactive Protein); mRNA: messenger Ribonucleic Acid; COVID-19: coronavirus disease 2019; PT: Prothrombin
Time; PTT: Partial Thromboplastin Time; INR: International Normalized Ratio; aPTT: activated Partial Thromboplastin Time.

11
 12
Table 4. Summary of reports of CVST with ischemic or hemorrhagic stroke.

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author,
cases (F, M) between year, ref
vaccination and
diagnosis
ChAdOx1 23 21-77 6-24 (mean:12) NM Thirteen cases of CVST NM Seven patients Scully et al.,
nCoV-19 (mean:46) Two cases of ischemic died 202169
(AstraZeneca) F = 14 M = 9 stroke
Positive antiPF4 antibody
in 22 patients
Thrombocytopenia in 22
patients, low fibrinogen
levels in 13 patients, and
increased D-dimer lev-
els in 21 patients
ChAdOx1 1 50 11 Headache, slight deviation of ICH Bilateral decompres- Brain death Castelli et al.,
nCoV-19 M=1 the right buccal rim, loss of CVST sive craniectomy 202171
(AstraZeneca) strength in the right lower Thrombocytopenia, low
limb, unstable walking, and fibrinogen level,
slight visual impairment increased amounts of D-
dimer, CRP, and
homocysteine
ChAdOx1 1 54 12 Left side signs ICH NM Death D’Agostino
nCoV-19 F=1 CVST et al.,
(AstraZeneca) Thrombocytopenia, and 202172
elevated D-dimer level
ChAdOx1 1 50 11 Headache, unconsciousness ICH Red blood cell and Death Franchini et
nCoV-19 M=1 CVST platelet apheresis al., 202173
(AstraZeneca) Thrombocytopenia, posi- transfusion, infusion
tive anti-PF4 antibody, of fibrinogen concen-
increased prothrombin trate, neurosurgical
time and D-dimer, low intervention
fibrinogen level, hypo-
homocysteinemia, and
low folic acid level

M. KAKOVAN ET AL.
 STROKE ASSOCIATED WITH COVID-19 VACCINES
Table 4 (Continued)

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author,
cases (F, M) between year, ref
vaccination and
diagnosis
ChAdOx1 2 Case 1 = 25, Case 1 = 6, Case Case 1: thunderclap head- ICH, SAH Case 1: no specific Brain stem Mehta et al.,
nCoV-19 Case 2=9 ache, left- incoordination, CVST hematological or death 202174
(AstraZeneca) 2 = 32 and hemiparesis Thrombocytopenia and immunological treat-
M=2 Case 2: headache with photo- low fibrinogen level ments were adminis-
phobia, neck stiffness, tered
visual disturbances, associ- Case 2: UFH, platelet
ated with a non-blanching transfusions, dexa-
petechial rash over lower methasone, IVIg
limbs, bleeding of gums,
left hemiparesis and hemi-
sensory loss, and focal
motor seizures
ChAdOx1 1 In early 30s 10 Mild myalgia, holocephalic CVST Argatroban, IVIg, and Persistent mini- Ikenberg et
nCoV-19 F=1 headache, chills, and per- ICH argatroban mal gait ataxia al., 202176
(AstraZeneca) sisting headaches Thrombocytopenia, posi- and amnestic
tive anti-PF4 antibody, deficits
elevated D-dimer level
ChAdOx1 1 69 13 Headache associated with CVST NM Brain death Jamme et al.,
nCoV-19 F=1 behavioral symptoms and ICH 2021104
(AstraZeneca) decreased level of Thrombocytopenia, posi-
consciousness tive anti-PF4 antibody
ChAdOx1 1 33 12 Headache, vomiting, sudden ICH, SAH, and CVT FFP, platelet concen- Death Choi et al.,
nCoV-19 M=1 onset of a tingling in the Thrombocytopenia, ele- trate, IVIg, methyl- 2021105
(AstraZeneca) right arm, mental change, vated D-dimer level, prednisolone, and
drowsiness, dysarthria, and low fibrinogen level, and thrombectomy
right hemiparesis positive anti-PF4
antibody
(Continued)

13
 14
Table 4 (Continued)

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author,
cases (F, M) between year, ref
vaccination and
diagnosis
ChAdOx1 3 22-46 7-17 Case 1: new frontally accen- Case 1:CVST, SAH Case 1: endovascular Case 1: mRS 0 Wolf et al.,
nCoV-19 F=3 tuated headache, a self-lim- Case 2: CVST. ICH rheolysis, levetirace- Case 2: mRS 1 2021106
ited generalized epileptic Case 3: CVST tam, enoxaparin, and Case 3: mRS 0
seizure Thrombocytopenia and dabigatran
Case 2: severe headache, positive anti-PF4 anti- Case 2: enoxaparin,
mild aphasia, hemianopia to body in all the three danaparoid, and
the right, somnolence patients dabigatran
Case 3: severe headache, Case 3: danaparoid,
acute somnolence and right- endovascular rheoly-
hand hemiparesis sis, enoxaparin, and
dabigatran
ChAdOx1 11 22-49 5-16 NM CVST in 9 patients NM Death in 6 Greinacher
nCoV-19 F = 9: M = 2 ICH in one patient patients, et al.,
(AstraZeneca) Thrombocytopenia in all recovery in 4 202178
of the patients, and posi- patients,
tive anti-PF4 antibody in No information
one patient about one
patient

M. KAKOVAN ET AL.
 STROKE ASSOCIATED WITH COVID-19 VACCINES
Table 4 (Continued)

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author,
cases (F, M) between year, ref
vaccination and
diagnosis
ChAdOx1 4 41-67 5-11 Case 1: headache, somno- Case 1: CVST and ICH Case 1: heparin and Case 1: Recov- Tiede et al.,
nCoV-19 F=4 lence, dysphasia, right hem- Case 2: cortical infarc- eculizumab ering 2021107
(AstraZeneca) iparesis, and arterial tions and aortic arch Case 2: argatroban and Case 2, 3, and 4:
hypertension thrombi IVIg Recovered
Case 2: headache Case 3: no pathology in Case 3: argatroban
Case 3: headache and diplo- imaging findings Case 4: argatroban and
pia Case 4: ischemic stroke in IVIg
Case 4: headache, dysarthria, ICA and MCA territory
left- hemiplegia, and conju- with hemorrhagic trans-
gated gaze palsy formation
Thrombocytopenia,
increased D-dimer level,
positive anti-PF4 anti-
body in all of the
patients

ChAdOx1 4 37-54 7-10 Case 1: fever and persistent Case 1: CVST and ICH Case 1: platelet trans- Case 1: death Schultz et
nCoV-19 F= 4 headaches Case 2: CVST and hemor- fusions and decom- Case 2: death al., 202193
(AstraZeneca) Case 2: headaches, reduced rhagic infarction pressive craniectomy Case 3: full
consciousness Case 3: CVT and hemor- Case 2: hemicraniec- recovery
Case 3: headache rhagic infarction tomy, dalteparin, Case 4: death
Case 4: hemiparesis Case 4: ICH and CVT methylprednisolone,
Thrombocytopenia and IVIg
positive anti-PF4 anti- Case 3: dalteparin,
body in all of the prednisolone and
patients IVIg
Case 4: platelet trans-
fusion, methylpred-
nisolone, IVIg,
thrombectomy, UFH,
and decompressive
hemicraniectomy
(Continued)

15
 16
Table 4 (Continued)

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author,
cases (F, M) between year, ref
vaccination and
diagnosis
ChAdOx1 1 27 12 Intermittent headache associ- CVST IVIg, dabigatan, idaru- Death Suresh et al.,
nCoV-19 M=1 ated with eye floaters and ICH cizumab, and 202126
(AstraZeneca) vomiting. Thrombocytopenia, posi- prednisolone
tive anti-PF4 antibody,
raised D- dimer, low
platelets, and fibrinogen
levels
ChAdOx1 1 62 13 Fever, weakness in the right CVST, Antibiotics, platelet Death B
erezn
e et
nCoV-19 M=1 arm, and mental confusion SAH, concentrate, UFH, al., 2021108
(AstraZeneca) Large parietal hematoma intravenous
(after receiving hepa- methylprednisolone
rin),
Acute myocardial infarc-
tion
Increased CRP, leukocy-
tosis, thrombocytopenia,
increased D-dimer level,
increased high-sensitiv-
ity cardiac troponin I
level, positive anti-PF4
antibody
ChAdOx1 1 32 11 Headache associated with CVST and Enoxaparin, parietal Discharged with Kotal et al.,
nCoV-19 F=1 blurredvision and giddiness, ICH decompressive hemi- home neurore- 2021109
(Covishield) weakness on the left upper Thrombocytopenia, craniectomy, fonda- habilitation
and lower limb increased D-dimer, posi- parinux, IVIg, service
tive anti-PF4 antibody tracheostomy

M. KAKOVAN ET AL.
 STROKE ASSOCIATED WITH COVID-19 VACCINES
Table 4 (Continued)

Vaccine Number of Age Gender Interval (days) Clinical presentation Imaging and lab findings Treatment Outcome Author,
cases (F, M) between year, ref
vaccination and
diagnosis
Ad26.COV2.S 12 18-60 6-15 Eleven patients initially pre- CVST Heparin treatment Death (n = 3), See et al.,
(Johnson & F = 12 sented with headache and (of the 12 patients with (later changed to ICU care 2021110
Johnson/ one patient initially showed CVST, seven also had non-heparin antico- (n = 3), non-
Jansen) back pain and later devel- ICH) agulant) in 6 ICU hospitali-
oped a headache Thrombocytopenia and patients; zation (n = 2),
elevated D-dimer level No and dis-
and decreased fibrino- anticoagulant therapy charged
gen level in 2 patients (n = 4)
Non-heparin anticoag-
ulant initially for
CVST treatment in 4
patients. In addition
to anticoagulation,
seven patients
received IVIg of
which three also
received systemic
corticosteroids and
four had platelet
transfusions.
mRNA-1273 1 45 8 Headache, neck pain, altered ICH,SAH, and Heparin and coumadin Discharged with Syed et al.,
M=1 mental, state after a wit- CVST no neurologi- 2021111
nessed seizure (GCS: 3) cal sequel
BNT162b2 2 47, 67 3, 6 Case 1: persistent headache, Case 1: CVST and SAH Case 1: enoxaparin and Case 1: slight Dias et al.,
mRNA(Pfizer) F=2 nausea, photophobia, and Case 2: CVST warfarin gait instability 2021112
sudden left motor deficit Case 2: enoxaparin, at two-month
Case 2: sudden right lower and dabigatran follow-up
limb clonic movements fol- Case 2:
lowed by motor deficit, loss discharged
of consciousness, and without neuro-
headache logical deficits
(Continued)

17
18 M. KAKOVAN ET AL.

Note: MCA: Middle Cerebral Artery; ICA: Internal Carotid Artery; CVST: Cerebral Venous Sinus Thrombosis; CVT: Cerebral Venous Thrombosis; Anti-PF4-antibody: anti-platelet factor 4 anti-
body; ICH: Intracerebral Hemorrhage; SAH: Subarachnoid Hemorrhage; LMWH: Low Molecular Weight Heparin; IVIg: Intravenous Immunoglobulin; UFH: Unfractionated Heparin; ICU: Inten-
Furthermore, continuing systemic anticoagulation for at

Cases 1 and 2: Fan et al.,

least three months in patients with documented thrombo-

2021113
year, ref
Author, sis in the context of VITT is recommended.130 However,
warfarin is not recommended in this setting due to a para-
doxical increase in thrombotic tendency.129 In order to

Case 2: UFH, LMWH, resis, on reha-

Left hemipa-
continue these VITT treatment recommendations, platelet

pressive craniectomy Case 3: Full

transfusions should be avoided unless the bleeding is

warfarin, and decom- bilitation

recovery
Outcome

associated with paradoxical thrombosis, and risk/benefit

assessment should be conducted in patients with severe
bleeding and/or the need for surgical intervention.116,117
Severe bleeding and/or the need for surgical intervention
may favor platelet transfusion following the initiation of
Case 1: UFH and

Case 3: LMWH,
IVIg, non-heparin anti-coagulation, and fibrinogen
replacement if its level is less than 1.5 g/L.116,117 Platelet

sive Care Unit; mRS: modified Rankin Scale; NM: Not Mentioned; CRP: C-Reactive Protein; FFP: Fresh Frozen Plasma; GCS: Glasgow Coma Scale.
Treatment

LMWH

transfusion should be considered in life-threatening

warfarin

bleeding situations.128 In other words, platelet transfusion

is an optional treatment to support anticoagulation, and
its superiority to critical care by argatroban (low dose)
Imaging and lab findings

without platelet transfusion has not yet been

Case 1: headache, vomiting, Case 1: ICH and CVST
Case 2: ICH, SAH, and

Case 3: ICH, SAH, and

confirmed.116,117 Expressly, if urgent neurosurgical inter-

vention is needed, platelet transfusion to >100 £ 109/L
and cryoprecipitate to maintain fibrinogen over 1.5 g/L
should be considered.116,117 However, since it is still
CVST

CVST

unclear that platelet transfusion can exacerbate CVST, a

definite recommendation cannot be given.128 In addition,
Table 4 (Continued)

fibrin injection is controversial, and it should be measured

Case 2: headache and vomit-

to ensure that its level does not drop below 1.5 g/L.128
Moreover, steroids may be useful, although whether their
benefits outweigh the potential harm is uncertain.128
and left hemiparesis
Age Gender Interval (days) Clinical presentation

Case 3: right ataxic

Plasma exchange could also be helpful in patients with

severe or resistant diseases. For VITT patients who are
hemiparesis

refractory relative to repeated doses of IVIg treatment

and plasma exchange, treatment with rituximab may be
helpful.128 In addition to pharmacological treatments,
ing

non-pharmacological methods such as Endovascular

Mechanical Thrombectomy (EMT) can be efficient for
vaccination and

selected patients. EMT can restore normal venous out-

flow, decrease venous congestion, and reduce increased
diagnosis
between

ICP through rapid and definite recanalization of occluded

venous sinuses.131,132 Wolf et al.106 reported 3 cases of
2-9

CVT after COVID-19 vaccination who were successfully

F=2M=1

treated by endovascular rheolysis. Although the outcome

of EMT in the case report by Choi et al105 was not satisfac-
(F, M)

54-62

tory, they suggested that if the EMT is done at early

stages, and before the beginning of cortical venous occlu-
sion, the outcome might be better. Therefore, if VITT-asso-
ciated CVT is clinically suspected and the symptoms
Number of

deteriorate quickly, early EMT intervention is neces-

sary.105 Another non-pharmacological procedure is
cases

decompressive craniectomy, which should be decided

3

based on the patient's condition. The association between

decompressive hemicraniectomy and the poor outcome
BNT162b2

Biontech

probably reflects the selection of patients with the most

(Pfizer-
mRNA
Vaccine

serious CVT for this invasive procedure.92

Anticoagulation with argatroban can be a useful treat-
ment option for VITT among other medications. This is
STROKE ASSOCIATED WITH COVID-19 VACCINES 19

because, first of all, it has a short half-life, which is useful References

in case of bleeding complications.100 Second, it also inhib-
its platelets.133 Third, a thrombin inhibitor acts at the bot- 1. Drosten C, G€ unther S, Preiser W, et al. Identification of a
novel coronavirus in patients with severe acute respira-
tom of the coagulation cascade with less potential effect
tory syndrome. N Engl J Med 2003;348:1967-1976.
on the other coagulation factors.100 Furthermore, bivaliru- 2. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isola-
din can be used as a heparin alternative in VITT for its tion of a novel coronavirus from a man with pneumonia
immediate onset of action, renal elimination, short half- in Saudi Arabia. N Engl J Med 2012;367:1814-1820.
life (w25 min), and ease of reversibility in the event of life- 3. Organization WH. Coronavirus disease 2019 (COVID-
19). Situation report 51. 2020. Accessed April 13, 2021.
threatening bleeding.101
4. Zhou P, Yang XL, Wang XG, et al. A pneumonia out-
break associated with a new coronavirus of probable
Conclusion bat origin. Nature 2020;579:270-273.
5. Zhu N, Zhang D, Wang W, et al. A novel coronavirus
Many recent studies reported the occurrence of stroke from patients with pneumonia in China, 2019. N Engl J
after administration of COVID-19 vaccination. All forms Med 2020;382:727-733.
of stroke including ischemic, ICH, and CVST have been 6. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety
encountered. Most of the evidence pertaining to stroke and immunogenicity of ChAdOx1 nCoV-19 vaccine
administered in a prime-boost regimen in young and
following COVID-19 vaccination are case reports, there-
old adults (COV002): a single-blind, randomised, con-
fore, the incidence of stroke after COVID-19 vaccination is trolled, phase 2/3 trial. Lancet North Am Ed
not precisely known. Most patients who suffered from 2020;396:1979-1993.
stroke after COVID-19 vaccination were women, under 7. Voysey M, Clemens SAC, Madhi SA, et al. Safety and
60 years of age, and after the ChAdOx1 nCoV-19 vaccine. efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
against SARS-CoV-2: an interim analysis of four rando-
Clinicians should be aware of the possible stroke after
mised controlled trials in Brazil, South Africa, and the
COVID-19 vaccination to ensure rapid diagnosis and UK. Lancet North Am Ed 2021;397:99-111.
treatment. CVST is an important phenomenon that may 8. Jackson LA, Anderson EJ, Rouphael NG, et al. An
occur after COVID-19 vaccination and is mostly associ- mRNA vaccine against SARS-CoV-2 -preliminary
ated with VITT. The diagnosis of VITT-associated stroke report. N Engl J Med 2020;383:1920-1931.
9. Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-
should be made with high suspicion because of its rapid
CoV-2 recombinant spike protein nanoparticle vaccine.
and diverse clinical manifestations. Stroke should be con- N Engl J Med 2020;383:2320-2332.
sidered when a patient develops any neurological com- 10. Walsh EE, Frenck RW, Falsey AR, et al. Safety and
plaints, especially constant headaches, within 4 weeks of immunogenicity of Two RNA-Based Covid-19 vaccine
COVID-19 vaccination. These patients should urgently be candidates. N Engl J Med 2020;383:2439-2450.
11. Anderson RM, Vegvari C, Truscott J, et al. Challenges in
evaluated for possible VITT with laboratory tests such as
creating herd immunity to SARS-CoV-2 infection by
platelet count, D-dimer, anti-PF4 antibody, fibrinogen mass vaccination. Lancet 2020;396:1614-1616. (London,
level, and brain imaging, especially cerebral venography. England).
Concurrent thrombosis including DVT, PTE, and splanch- 12. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immu-
nic venous thrombosis should be ruled out in patients nogenicity of the ChAdOx1 nCoV-19 vaccine against
SARS-CoV-2: a preliminary report of a phase 1/2, sin-
who suffered from VITT-associated CVST. Furthermore,
gle-blind, randomised controlled trial. Lancet
other differential diagnoses including APS, DIC, ITP, 2020;396:467-478. (London, England).
thrombotic-thrombocytopenic purpura, atypical hemo- 13. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and
lytic uremic syndrome, paroxysmal nocturnal hemoglo- immunogenicity of an inactivated SARS-CoV-2 vaccine
binuria, and underlying malignant diseases should be in healthy adults aged 18 59 years: a randomised, dou-
ble-blind, placebo-controlled, phase 1/2 clinical trial.
taken into account. Notably, the latest guidelines should
Lancet Infect Dis 2021;21:181-192.
be considered for VITT management; however, clinicians 14. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and
should eventually act according to the specific condition safety of a recombinant adenovirus type-5-vectored
of each patient. Since the management of VITT is chal- COVID-19 vaccine in healthy adults aged 18 years or
lenging, they should be managed by a multidisciplinary older: a randomised, double-blind, placebo-controlled,
phase 2 trial. Lancet 2020;396:479-488. (London, Eng-
team from different disciplines including hematology,
land).
neurology, stroke, neurosurgery, and neuroradiology. 15. Kantarcioglu B, Iqbal O, Walenga JM, et al. An Update
Finally, since the advantages of COVID-19 vaccination on the Pathogenesis of COVID-19 and the reportedly
outweigh the risk of stroke or any other neurological com- rare thrombotic events following vaccination. Clin Appl
plication, the public should be reassured that the vaccina- Thromb Hemost 2021;27:10760296211021498. official
journal of the International Academy of Clinical and
tion program is still the best way to combat COVID-19.
Applied Thrombosis/Hemostasis.
16. Finney Rutten LJ, Zhu X, Leppin AL, et al. Evidence-
Declaration of Competing Intrest based strategies for clinical organizations to address
COVID-19 vaccine hesitancy. Mayo Clin Proc
The authors declare no conflict of interest with respect 2021;96:699-707.
to the present review study.
20 M. KAKOVAN ET AL.

17. Kreps S, Prasad S, Brownstein JS, et al. Factors associ- 35. Sankowski R, Mader S, Vald
es-Ferrer SI. Systemic
ated with US Adults' likelihood of accepting COVID-19 inflammation and the brain: novel roles of genetic,
vaccination. JAMA Netw Open 2020;3:e2025594. molecular, and environmental cues as drivers of neuro-
18. Pogue K, Jensen JL, Stancil CK, et al. Influences on atti- degeneration. Front Cell Neurosci 2015;9:28.
tudes regarding potential COVID-19 vaccination in the 36. Wu Y, Xu X, Chen Z, et al. Nervous system involvement
United States. Vaccines 2020;8:582. after infection with COVID-19 and other coronaviruses.
19. Andalib S, Biller J, Di Napoli M, et al. Peripheral ner- Brain Behav Immun 2020;87:18-22.
vous system manifestations associated with COVID-19. 37. Mikaeloff Y, Caridade G, Suissa S, et al. Hepatitis B vac-
Curr Neurol Neurosci Rep 2021;21:9. cine and the risk of CNS inflammatory demyelination in
20. Divani AA, Andalib S, Di Napoli M, et al. Coronavirus childhood. Neurology 2009;72:873-880.
disease 2019 and stroke: clinical manifestations and 38. Scheller NM, Svanstr€ om H, Pasternak B, et al. Quadriva-
pathophysiological insights. Association lent HPV vaccination and risk of multiple sclerosis and
2020;29:104941. other demyelinating diseases of the central nervous sys-
21. Behzadnia H, Omrani SN, Nozari-Golsefid H, et al. tem. JAMA 2015;313:54-61.
Ischemic stroke and intracerebral hemorrhage in 39. Karussis D, Petrou P. The spectrum of post-vaccination
patients with COVID-19. Rom J Neurol 2020;19:166-170. inflammatory CNS demyelinating syndromes. Autoim-
22. Singh Malhotra H, Gupta P, Prabhu V, et al. COVID-19 mun Rev 2014;13:215-224.
vaccination-associated myelitis. QJM: monthly journal 40. McMahon AW, Eidex RB, Marfin AA, et al. Neurologic
of the Association of Physicians 2021. disease associated with 17D-204 yellow fever vaccina-
23. Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cere- tion: a report of 15 cases. Vaccine 2007;25:1727-1734.
bral haemorrhage after COVID-19 vaccine. Tidsskr Nor 41. Pruna D, Balestri P, Zamponi N, et al. Epilepsy and vac-
Laegeforen 2021:141. tidsskrift for praktisk medicin, ny cinations: Italian guidelines. Epilepsia 2013;54:13-22.
raekke. Suppl 7.
24. Schultz NH, Sørvoll IH, Michelsen AE, et al. Brief 42. Waheed S, Bayas A, Hindi F, et al. Neurological compli-
Report: Thrombosis and Thrombocytopenia after ChA- cations of COVID-19: guillain-barre syndrome following
dOx1 nCoV-19 Vaccination. The New England journal pfizer COVID-19 vaccine. Cureus 2021;13:e13426.
of medicine. 43. Goss AL, Samudralwar RD, Das RR, et al. ANA Investi-
25. Piazza G. Cerebral venous thrombosis. Circulation gates: neurological complications of COVID-19 vac-
2012;125:1704-1709. cines. Ann Neurol 2021;89:856-857.
26. Suresh P, Petchey W. ChAdOx1 nCOV-19 vaccine- 44. Ledford H. US authorization of first COVID vaccine
induced immune thrombotic thrombocytopenia and marks new phase in safety monitoring. Nature
cerebral venous sinus thrombosis (CVST). BMJ Case 2020;588:377-378.
Rep 2021;14:e243931. 45. Moadabi Y, Rezaei M, Homaei-Rad E, et al. Pineal gland
27. Al-Mayhani T, Saber S, Stubbs MJ, et al. Ischaemic calcification confirmed by CT scan is associated with
stroke as a presenting feature of ChAdOx1 nCoV-19 ischemic stroke. Rom J Neurol 2019;18.
vaccine-induced immune thrombotic thrombocytope- 46. Andalib S, Lattanzi S, Di Napoli M, et al. Blood pressure
nia. J Neurol Neurosurg Psychiatry 2021;92:1247-1248. variability: a new predicting factor for clinical outcomes
28. Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced of intracerebral hemorrhage. J Stroke Cerebrovasc Dis
Immune Thrombotic Thrombocytopenia. N Engl J Med 2020;29:105340. the official journal of National Stroke
2021;384:2254-2256. Association.
29. Myoclinic: Different types of COVID-19 vaccines: how 47. Saposnik G, Barinagarrementeria F, Brown RD, American
they work. Availabe online: https://www.mayoclinic. heart association stroke council and the council on epide-
org/diseases-conditions/coronavirus/in-depth/differ- miology and prevention. Diagnosis and management of
ent-types-of-covid-19-vaccines/art-20506465 (accessed cerebral venous thrombosis: a statement for healthcare
on 6 Oct 2021) professionals from the American heart association/Ameri-
30. WHO: Coronavirus disease (COVID-19): Vaccines. can stroke association. Stroke 2011;42:1158-1192.
Availabe online: https://www.who.int/news-room/q- 48. Ferro JM, Bousser MG, Canh~ ao P, et al. European stroke
a-detail/coronavirus-disease-(covid-19)-vaccines?topic- organization guideline for the diagnosis and treatment
survey=v8kj13)&gclid=CjwKCAjwn8SLBhAyEi- of cerebral venous thrombosis endorsed by the Euro-
wAHNTJbcnirkqgcFnvxtKY_Qhc0pAoGWMoxlhxogw- pean Academy of Neurology. Eur Stroke J 2017;2:195-
CI5aQLCIYCQmfj7MSPhoCrScQAvD_BwE# (accessed 221.
on 28 October 2020) 49. Silvis SM, De Sousa DA, Ferro JM, et al. Cerebral venous
31. Hosseini SA, Zahedipour F, Mirzaei H, et al. Potential thrombosis. Nat Rev Neurol 2017;13:555-565.
SARS-CoV-2 vaccines: Concept, progress, and chal- 50. Pontara E, Cheng C, Cattini M, et al. An in vitro model to
lenges. Int Immunopharmacol 2021;97:107622. mimic the thrombotic occlusion of small vessels in cata-
32. Huang C, Wang Y, Li X, et al. Clinical features of strophic antiphospholipid syndrome (CAPS). Lupus
patients infected with 2019 novel coronavirus in 2019;28:1663-1668.
Wuhan, China. Lancet 2020;395:497-506. (London, Eng- 51. Marcucci R, Marietta M. Vaccine-induced thrombotic
land). thrombocytopenia: the elusive link between thrombosis
33. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteris- and adenovirus-based SARS-CoV-2 vaccines. Internal
tics of bronchoalveolar lavage fluid and peripheral Emerg Med 2021:1-7.
blood mononuclear cells in COVID-19 patients. Emerg 52. IMD - Uptodate: COVID-19: vaccine-induced immune
Microbes Infect 2020;9:761-770. thrombotic thrombocytopenia (VITT). Available online:
34. Divani AA, Andalib S, Biller J, et al. Central nervous sys- https://www.uptodate.com/contents/covid-19-vac-
tem manifestations associated with COVID-19. Curr cine-induced-immune-thrombotic-thrombocytopenia-
Neurol Neurosci Rep 2020;20:60. vitt/print (last updated on 30 Sep 2021).
STROKE ASSOCIATED WITH COVID-19 VACCINES 21

53. Blauenfeldt RA, Kristensen SR, Ernstsen SL, et al. 71. Castelli GP, Pognani C, Sozzi C, et al. Cerebral venous
Thrombocytopenia with acute ischemic stroke and sinus thrombosis associated with thrombocytopenia
bleeding in a patient newly vaccinated with an adenovi- post-vaccination for COVID-19. Crit Care 2021;25:137.
ral vector-based COVID-19 vaccine. J Thromb Haemost 72. D’Agostino V, Caranci F, Negro A, et al. A rare case of
JTH 2021;19:1771-1775. cerebral venous thrombosis and disseminated intravas-
54. Greinacher A, Selleng K, Warkentin T. Autoimmune cular coagulation temporally associated to the COVID-
heparin-induced thrombocytopenia. J Thromb Haemost 19 vaccine administration. J Personal Med 2021;11:285.
2017;15:2099-2114. 73. Franchini M, Testa S, Pezzo M, et al. Cerebral venous
55. Cavalcanti DD, Raz E, Shapiro M, et al. Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vac-
thrombosis associated with COVID-19. Am J Neurora- cination. Thromb Res 2021;202:182-183.
diol 2020;41:1370-1376. 74. Mehta PR, Apap Mangion S, Benger M, et al. Cerebral
56. Sukrita B, Banerjee M. Immune thrombocytopenia sec- venous sinus thrombosis and thrombocytopenia after
ondary to COVID-19: a systematic review. 2020. COVID-19 vaccination-a report of two UK cases. Brain
57. Greinacher A, Selleng K, Mayerle J, et al. Anti-SARS- Behav Immun 2021;95:514-517.
CoV-2 spike protein and anti-platelet factor 4 antibody 75. de Melo Silva ML, Lopes DP. Large hemorrhagic stroke
responses induced by COVID-19 disease and ChAdOx1 after ChAdOx1 nCoV-19 vaccination: a case report. Acta
nCov-19 vaccination. 2021. Neurol Scand 2021.
58. Ciccone A. SARS-CoV-2 vaccine-induced cerebral 76. Ikenberg B, Demleitner AF, Thiele T, et al. Cerebral
venous thrombosis. Eur J Intern Med 2021;89:19-21. venous sinus thrombosis after ChAdOx1 nCov-19 vacci-
59. Taquet M, Husain M, Geddes JR, et al. Cerebral venous nation with a misleading first cerebral MRI scan. Stroke
thrombosis and portal vein thrombosis: a retrospective Vasc Neurol 2021.
cohort study of 537,913 COVID-19 cases. EClinicalMedi- 77. Meylan S, Livio F, Foerster M, et al. Stage III hyperten-
cine 2021;39:101061. sion in patients after mRNA-based SARS-CoV-2 vacci-
60. Liu T, Dai J, Yang Z, et al. Inactivated SARS-CoV-2 vac- nation. Hypertension 2021;77. (Dallas, Tex: 1979)e56-
cine does not influence the profile of prothrombotic anti- e57.
body nor increase the risk of thrombosis in a prospective 78. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic
Chinese cohort. Sci Bull 2021;66:2312-2319. thrombocytopenia after ChAdOx1 nCov-19 vaccination.
61. Campello E, Simion C, Bulato C, et al. Absence of hyper- N Engl J Med 2021;384:2092-2101.
coagulability after nCoV-19 vaccination: an observa- 79. Finsterer J, Korn M. Aphasia seven days after second
tional pilot study. Thromb Res 2021;205:24-28. dose of an mRNA-based SARS-CoV-2 vaccine. Brain
62. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChA- Hemorrhages 2021;2:165-167.
dOx1 and BNT162b2 COVID-19 vaccines and thrombo- 80. Wolthers SA, Stenberg J, Nielsen HB, et al. [Intracerebral
cytopenic, thromboembolic and hemorrhagic events in haemorrhage twelve days after vaccination with ChA-
Scotland. Nat Med 2021;27:1290-1297. dOx1 nCoV-19]. Ugeskr Laeger 2021;183.
63. Nicolai L, Leunig A, Pekayvaz K, et al. Thrombocytope- 81. Sadeghi-Hokmabadi E, Sakhinia E, Farhoudi M, et al.
nia and splenic platelet directed immune responses after Common prothrombotic gene mutations in cerebral
intravenous ChAdOx1 nCov-19 administration. bioRxiv venous sinus thrombosis in North-West of Iran. Neuro-
2021:2021.2006.2029.450356. sci Med 2017;8:68-76.
64. De Michele M, Iacobucci M, Chistolini A, et al. Malig- 82. Thakur KT, Tamborska A, Wood GK, et al. Clinical
nant cerebral infarction after ChAdOx1 nCov-19 vacci- review of cerebral venous thrombosis in the context of
nation: a catastrophic variant of vaccine-induced COVID-19 vaccinations: evaluation, management, and
immune thrombotic thrombocytopenia. Nat Commun scientific questions. J Neurol Sci 2021;427:117532.
2021;12:4663. 83. Dakay K, Cooper J, Bloomfield J, et al. Cerebral venous
65. Staessens S, Denorme F, Francois O, et al. Structural sinus thrombosis in COVID-19 infection: a case series
analysis of ischemic stroke thrombi: histological indica- and review of the literature. J Stroke Cerebrovasc Dis
tions for therapy resistance. Haematologica 2020:105434.
2020;105:498-507. 84. Smadja DM, Yue QY, Chocron R, et al. Vaccination
66. Reilly MP, Taylor SM, Hartman NK, et al. Heparin- against COVID-19: insight from arterial and venous
induced thrombocytopenia/thrombosis in a transgenic thrombosis occurrence using data from VigiBase. Eur
mouse model requires human platelet factor 4 and plate- Respir J 2021;58.
let activation through FcgammaRIIA. Blood 85. Douxfils J, Favresse J, Dogn
e JM, et al. Hypotheses
2001;98:2442-2447. behind the very rare cases of thrombosis with thrombo-
67. Towne JB, Bernhard VM, Hussey C, et al. White clot cytopenia syndrome after SARS-CoV-2 vaccination.
syndrome. Peripheral vascular complications of heparin Thromb Res 2021;203:163-171.
therapy. Arch Surg 1979;114:372-377. (Chicago, Ill: 86. Franchini M, Liumbruno GM, Pezzo M. COVID-19 Vac-
1960). cine-associated Immune Thrombosis and Thrombocyto-
68. Garnier M, Curado A, Billoir P, et al. Imaging of penia (VITT): diagnostic and therapeutic
Oxford/AstraZenecaÒ COVID-19 vaccine-induced recommendations for a new syndrome. Eur J Haematol
immune thrombotic thrombocytopenia. Diagn Interv 2021;107:173-180.
Imaging 2021;102:649-650. 87. Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis
69. Scully M, Singh D, Lown R, et al. Pathologic antibodies and thrombocytopenia after ChAdOx1 nCoV-19 vacci-
to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. nation. N Engl J Med 2021;384:2124-2130.
N Engl J Med 2021;384:2202-2211. 88. Bikdeli B, Chatterjee S, Arora S, et al. Cerebral venous
70. Walter U, Fuchs M, Grossmann A, et al. Adenovirus- sinus thrombosis in the US population, after adenovi-
vectored COVID-19 vaccine-induced immune thrombo- rus-based SARS-CoV-2 vaccination, and after COVID-
sis of carotid artery: a case report. Neurology 2021. 19. J Am Coll Cardiol 2021;78:408-411.
22 M. KAKOVAN ET AL.

89. Elalamy I, Gerotziafas G, Alamowitch S, et al. SARS- 105. Choi JK, Kim S, Kim SR, et al. Intracerebral hemorrhage
CoV-2 vaccine and thrombosis: an expert consensus on due to thrombosis with thrombocytopenia syndrome
vaccine-induced immune thrombotic thrombocytope- after vaccination against COVID-19: the first fatal case
nia. Thromb Haemost 2021. in Korea. J Korean Med Sci 2021;36:e223.
90. Stam J. Thrombosis of the cerebral veins and sinuses. N 106. Wolf ME, Luz B, Niehaus L, et al. Thrombocytopenia
Engl J Med 2005;352:1791-1798. and intracranial venous sinus thrombosis after
91. Sessa M, Kragholm K, Hviid A, et al. Thromboembolic “COVID-19 vaccine AstraZeneca” Exposure. J Clin Med
events in younger women exposed to Pfizer-BioNTech 2021;10:1599.
or Moderna COVID-19 vaccines. Expert Opin Drug Saf 107. Tiede A, Sachs UJ, Czwalinna A, et al. Prothrombotic
2021:1-3. immune thrombocytopenia after COVID-19 vaccination.
92. Perry RJ, Tamborska A, Singh B, et al. Cerebral venous Blood 2021;138:350-353.
thrombosis after vaccination against COVID-19 in the 108. B
erezn
e A, Bougon D, Blanc-Jouvan F, et al. Deteriora-
UK: a multicentre cohort study. Lancet 2021;398:1147- tion of vaccine-induced immune thrombotic thrombocy-
1156. (London, England). topenia treated by heparin and platelet transfusion:
93. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis Insight from functional cytometry and serotonin release
and Thrombocytopenia after ChAdOx1 nCoV-19 Vacci- assay. Res Pract Thromb Haemost 2021;5:e12572.
nation. N Engl J Med 2021;384:2124-2130. 109. Kotal R, Jacob I, Rangappa P, et al. A rare case of vac-
94. Krzywicka K, Heldner MR, S
anchez van Kammen cine-induced immune thrombosis and thrombocytope-
M, et al. Post-SARS-CoV-2-vaccination cerebral nia and approach to management. Surg Neurol Int
venous sinus thrombosis: an analysis of cases noti- 2021;12:408.
fied to the European Medicines Agency. Eur J Neu- 110. See I, Su JR, Lale A, et al. US case reports of cerebral
rol 2021;28:3656-3662. venous sinus thrombosis with thrombocytopenia after
95. Zakaria Z, Sapiai NA, Ghani ARI. Cerebral venous sinus Ad26.COV2.S vaccination, March 2 to April 21, 2021.
thrombosis 2 weeks after the first dose of mRNA SARS- JAMA 2021;325:2448-2456.
CoV-2 vaccine. Acta Neurochir 2021:1-4. (Wien). 111. Syed K, Chaudhary H, Donato A. Central venous sinus
96. Dutta A, Ghosh R, Bhattacharya D, et al. Anti-PF4 anti- thrombosis with subarachnoid hemorrhage following
body negative cerebral venous sinus thrombosis with- an mRNA COVID-19 vaccination: are these reports
out thrombocytopenia following immunization with merely Co-incidental? Am J Case Rep 2021;22:e933397.
COVID-19 vaccine in an elderly non-comorbid Indian 112. Dias L, Soares-Dos-Reis R, Meira J, et al. Cerebral
male, managed with conventional heparin-warfarin venous thrombosis after BNT162b2 mRNA SARS-CoV-
based anticoagulation. Diabetes Metab Syndr 2 vaccine. J Stroke Cerebrovasc Dis 2021;30:105906. the
2021;15:102184. official journal of National Stroke Association.
97. Guan CY, Tsai SH, Fan JS, et al. A rare case of a middle- 113. Fan BE, Shen JY, Lim XR, et al. Cerebral venous throm-
age Asian male with cerebral venous thrombosis after bosis post BNT162b2 mRNA SARS-CoV-2 vaccination:
COVID-19 AstraZeneca vaccination. Am J Emerg Med a black swan event. Am J Hematol 2021;96:E357-E361.
2021;51:427.e3-427.e4. 114. Hwang J, Lee SB, Lee SW, et al. Comparison of vaccine-
98. Geeraerts T, Montastruc F, Bonneville F, et al. Oxford- induced thrombotic events between ChAdOx1 nCoV-19
AstraZeneca COVID-19 vaccine-induced cerebral and Ad26.COV.2.S vaccines. J Autoimmun
venous thrombosis and thrombocytopaenia: a missed 2021;122:102681.
opportunity for a rapid return of experience. Anaesth 115. Pawlowski C, Rinc
on-Hekking J, Awasthi S, et al. Cere-
Crit Care Pain Med 2021:100889. bral venous sinus thrombosis is not significantly linked
99. Aladdin Y, Algahtani H, Shirah B. Vaccine-induced to COVID-19 vaccines or Non-COVID vaccines in a
immune thrombotic thrombocytopenia with dissemi- large multi-state health system. J Stroke Cerebrovasc
nated intravascular coagulation and death following the Dis 2021;30:105923. the official journal of National
ChAdOx1 nCoV-19 vaccine. J Stroke Cerebrovasc Dis Stroke Association.
2021;30:105938. the official journal of National Stroke 116. Pavord D, Makris M, Scully M, Hunt B. Guidance from
Association. the am panel (EHP) on Covid-19 vaccine-induced
100. Gattringer T, Gressenberger P, Gary T, et al. Successful immune thrombocytopenia and thrombosis (VITT).
management of vaccine-induced immune thrombotic Available online: https://b-s-h.org.uk/media/19590/
thrombocytopenia-related cerebral sinus venous throm- guidance-version-17 -on-mngmt-of-vitt-20210420.pdf
bosis after ChAdOx1 nCov-19 vaccination. Stroke Vasc (accessed on 17 May 2021).
Neurol 2021. 117. Bussel JM, Cines, DB, Dunbar, C, et al. Thrombosis with
101. Clark RT, Johnson L, Billotti J, et al. Early outcomes of thrombocytopenia syndrome (Also Termed Vaccine-
bivalirudin therapy for thrombotic thrombocytopenia Induced Thrombotic Thrombocytopenia). Available
and cerebral venous sinus thrombosis after Ad26.COV2. online: https: //www.hematology.org/covid-19/vac-
S vaccination. Ann Emerg Med 2021;78:511-514. cine-induced-immune-thrombotic-thrombocytopenia
102. Muir KL, Kallam A, Koepsell SA, et al. Thrombotic (accessed on 17 May 2021).
thrombocytopenia after Ad26.COV2.S vaccination. N 118. Garcia-Azorin D. Diagnostic and treatment recommen-
Engl J Med 2021;384:1964-1965. dations from the FACME ad-hoc expert working group
103. Malik B, Kalantary A, Rikabi K, et al. Pulmonary embo- on the management of cerebral venous sinus thrombosis
lism, transient ischaemic attack and thrombocytopenia associated with COVID-19 vaccination. Neurología
after the Johnson & Johnson COVID-19 vaccine. BMJ 2021;36:451-461. (English Edition).
Case Rep 2021;14. 119. Linn J, Pfefferkorn T, Ivanicova K, et al. Noncontrast CT
104. Jamme M, Mosnino E, Hayon J, et al. Fatal cerebral in deep cerebral venous thrombosis and sinus thrombo-
venous sinus thrombosis after COVID-19 vaccination. sis: comparison of its diagnostic value for both entities.
Intensiv Care Med 2021;47:790-791. AJNR Am J Neuroradiol 2009;30:728-735.
STROKE ASSOCIATED WITH COVID-19 VACCINES 23

120. Buyck PJ, Zuurbier SM, Garcia-Esperon C, et al. Diagnos- 128. Islam A, Bashir MS, Joyce K, et al. An update on
tic accuracy of noncontrast CT imaging markers in cere- COVID-19 vaccine induced thrombotic thrombocytope-
bral venous thrombosis. Neurology 2019;92:e841-e851. nia syndrome and some management recommenda-
121. Bonatti M, Valletta R, Lombardo F, et al. Accuracy of tions. Molecules 2021;26:5004.
unenhanced CT in the diagnosis of cerebral venous sinus 129. Mohseni Afshar Z, Babazadeh A, Janbakhsh A, et al.
thrombosis. Radiol Med 2021;126:399-404. (Torino). Vaccine-induced immune thrombotic thrombocytopenia
122. Tayyebi S, Akhavan R, Shams M, et al. Diagnostic value of after vaccination against Covid-19: a clinical dilemma
non-contrast brain computed tomography in the evaluation for clinicians and patients. Rev Med Virol 2021:e2273.
of acute cerebral venous thrombosis. Sci Rep 2020;10:883. 130. Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and
123. Xu W, Gao L, Li T, et al. The performance of CT versus management of vaccine-related thrombosis following
MRI in the differential diagnosis of cerebral venous astrazeneca COVID-19 vaccination: guidance statement
thrombosis. Thromb Haemost 2018;118:1067-1077. from the GTH. Hamostaseologie 2021;41:184-189.
124. Gao L, Xu W, Li T, et al. Accuracy of magnetic resonance 131. Lee SK, Mokin M, Hetts SW, et al. Current endovascular
venography in diagnosing cerebral venous sinus throm- strategies for cerebral venous thrombosis: report of the
bosis. Thromb Res 2018;167:64-73. SNIS standards and guidelines committee. J Neuroin-
125. Kennedy VE, Wong CC, Hong JM, et al. VITT following terv Surg 2018;10:803-810.
Ad26.COV2.S vaccination presenting without radio- 132. Ilyas A, Chen CJ, Raper DM, et al. Endovascular
graphically demonstrable thrombosis. Blood Adv 2021. mechanical thrombectomy for cerebral venous sinus
126. Cattaneo M. Thrombosis with Thrombocytopenia Syn- thrombosis: a systematic review. J Neurointerv Surg
drome associated with viral vector COVID-19 vaccines. 2017;9:1086-1092.
Eur J Intern Med 2021;89:22-24. 133. Lunven C, Gauffeny C, Lecoffre C, et al. Inhibition by
127. Warkentin TE. High-dose intravenous immunoglobulin for argatroban, a specific thrombin inhibitor, of platelet acti-
the treatment and prevention of heparin-induced thrombo- vation by fibrin clot-associated thrombin. Thromb Hae-
cytopenia: a review. Expert Rev Hematol 2019;12:685-698. most 1996;75:154-169.